Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy

Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy

Background: Cardiotoxicity associated with the sequential use of anthracyclines followed by trastuzumab is common in adjuvant therapy of patients with HER2-positive early breast cancer (eBC). However, the cardiac safety of trastuzumab concurrent with pegylated liposomal doxorubicin (PLD) is relative...

Full description

Bibliographic Details
Main Authors: Ping Huang, Jia-huan Huang, Ya-bing Zheng, Wen-ming Cao, Xi-ying Shao, Jun-qing Chen, Yuan Huang, Guang-liang Li, K Sharma, Huan-huan Zhou, Xiao-jia Wang, Hong-chuan Jin, Zhan-hong Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
cardiotoxicity
early breast cancer
HER2-positive
pegylated liposomal doxorubicin
trastuzumab
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.883600/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.883600/full

Similar Items